Evolus

EOLS

Market cap $465M

Overview Fund Activity

7.19 USD

-0.32

4.26%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

7.19

0.00

0%

1 day

-4.26%

5 days

-5.52%

1 month

12.34%

3 months

-29.37%

6 months

-46.42%

Year to date

-35.28%

1 year

-56.32%

5 years

95.91%

10 years

-37.48%

About: Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Employees: 394

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,954% more call options, than puts

Call options by funds: $12.1M | Put options by funds: $587K

28% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 50

5.09% more ownership

Funds ownership: 85.34% [Q1] → 90.43% (+5.09%) [Q2]

4% less funds holding

Funds holding: 179 [Q1] → 171 (-8) [Q2]

13% less funds holding in top 10

Funds holding in top 10: 8 [Q1] → 7 (-1) [Q2]

18% less capital invested

Capital invested by funds: $653M [Q1] → $537M (-$116M) [Q2]

21% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 34

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

150% upside

Avg. target

$20

178% upside

High target

$22

206% upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

BTIG Sam Eiber	$18	Buy Reiterated	8 Sep 2025
Needham Serge Belanger	$22	Hold Downgraded	6 Aug 2025
HC Wainwright & Co. Douglas Tsao	$20	Buy Maintained	6 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about EOLS published over the past 30 days

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,744 shares of Evolus common stock and an aggregate of 15,000 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company, and 143,403 shares of Evolus common stock and 104,603 RSUs of the com.

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and private companies in retail, consumer, data, and technology-driven businesses. She brings a proven track record of dri.

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. “Achieving positive topline results in our mid-face study is an important milestone for Evolus as we expand beyond Jeuveau® with the Evolysse™ line,” said David.

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. “This submission represents an important milestone in expanding our Evolysse™ col.

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in August of an aggregate of 12,731 restricted stock units (RSUs) of the company's common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant d.

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Motley Fool

Evolus (EOLS) Q2 Revenue Rises 4%

Evolus (EOLS) Q2 Revenue Rises 4%

Evolus (EOLS) Q2 Revenue Rises 4%

Zacks Investment Research

Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.07 per share a year ago.

Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

Evolus, Inc. (NASDAQ:EOLS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants David Moatazedi - President, CEO & Director Nareg Sagherian - Head of Global Investor Relations & Corporate Communications Rui Avelar - Chief Medical Officer and Head of Research & Development Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Douglas Dylan Tsao - H.C. Wainwright & Co, LLC, Research Division Marc Harold Goodman - Leerink Partners LLC, Research Division Navann Ty Dietschi - BNP Paribas Exane, Research Division Sam Shimon Eiber - BTIG, LLC, Research Division Serge D.

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2025. “U.S. toxin demand softened in the second quarter, driven by reduced patient demand due to a sharp decrease in consumer sentiment which resulted in accounts purchasing lower volumes acutely felt in the final two weeks of the quarter. Despite these cha.

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of a landmark independent study in JAMA Dermatology directly comparing four leading botulinum toxin type A products for the treatment of glabellar lines: Jeuveau® (prabotulinumtoxinA-xvfs), Botox® (onabotulinumtoxinA), Dysport® (abobotulinumtoxinA), and Xeomin® (incobotulinumtoxinA). In the double-bl.

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

See News Rankings

Charts implemented using Lightweight Charts™